Hyperinsulinemia in Prediabetes Mediated by Interleukin-1β

Inclusion Criteria: * Subjects with prediabetes defined by HbA1c 5.7-6.4 % or fasting plasma glucose 6.1-6.9 mmol/l or plasma glucose 2 h following 75g glucose ingestion of 7.8-11.0 mmol/l. * BMI ≥ 28 kg/m2 * Age ≥ 18 years * C-reactive protein ≥ 2 mg/dl * For subjects with reproductive potential, willingness to use contraceptive measures adequate to prevent the subject from becoming pregnant during the study Exclusion Criteria: * Upper gastrointestinal surgery * Diagnosis of any type of diabetes mellitus * Signs of current infection * Use of any glucose lowering medication within the last three months * Use of investigational drug up to one week prior to start of treatment phase. * Anti-inflammatory medication, including systemic glucocorticoid therapy. * Neutropenia (leukocyte count \< 1.5 × 109/L or absolute neutrophil count (ANC) \< 0.5 × 109/L) * Anemia (hemoglobin \< 11 g/dL for males, \< 10 g/dL for females) * Clinically significant kidney or liver disease (creatinine \> 1.5 mg/dL, aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) \> 2 × ULN, alkaline phosphatase \> 2 × ULN, or total bilirubin \[tBili\] \> 1.5 × ULN) * Uncontrolled disease * Currently pregnant or breastfeeding * No subjects meeting the criteria for vulnerability. Participation in another study with investigational drug within the 30 days preceding and during the present study